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Hareﬁeld NHS Fohronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic
pulmonary ﬁbrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH),
which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary ﬁbrosis and
emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization
are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1 PH patients with
concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be
transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force
encompassing the authors of this article provided criteria for this discrimination and suggested using the following
deﬁnitions for group3 patients, as exempliﬁed for COPD, IPF, and CPFE: COPD/IPF/CPFEwithoutPH (mean pulmonary
artery pressure [mPAP]<25mmHg); COPD/IPF/CPFEwith PH (mPAP25mmHg); PH-COPD, PH-IPF, and PH-CPFE);
COPD/IPF/CPFEwith severe PH (mPAP35mmHg ormPAP25mmHgwith low cardiac index [CI<2.0 l/min/m2];
severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The “severe PH group” includes only a minority of chronic lung
disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the
parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory
reserve underlying the limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests,
low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical
features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs
currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these
patients should be transferred to expert centers for individualized patient care. (J AmColl Cardiol 2013;62:D109–16)
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Abbreviations
and Acronyms
6MWD = 6-min walk
distance
BNP = brain natriuretic
peptide
CI = cardiac index
COPD = chronic obstructive
pulmonary disease
CPFE = combined pulmonary
ﬁbrosis and emphysema
CT = computed tomography
DLCO = diffusing capacity of
lung for carbon monoxide
DPLD = diffuse parenchymal
lung disease
ERA = endothelin receptor
antagonist
FEV1 = forced expiratory
volume in 1 s
FVC = forced vital capacity
IPAH = idiopathic pulmonary
arterial hypertension
IPF = idiopathic pulmonary
ﬁbrosis
mPAP = mean pulmonary
artery pressure
PaCO2 = partial pressure of
carbon dioxide in arterial
blood
PaO2 = partial pressure of
oxygen in arterial blood
PH = pulmonary
hypertension
PH-SA = pulmonary
hypertension in sarcoidosis
PVR = pulmonary vascular
resistance
RHC = right heart
catheterization
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D110Epidemiology and Clinical
Relevance of Pulmonary
Hypertension in Lung
Disease
Chronic obstructive pulmonary
disease. The prevalence of pul-
monary hypertension (PH) in
chronic obstructive pulmonary
disease (COPD) depends on the
severity of the disease and the
deﬁnition of PH (see discussion
in the following text). Several
studies in patients with the
previous GOLD (Global Initia-
tive for Chronic Obstructive
Lung Disease) stage IV showed
that up to 90% of these patients
have a mean pulmonary artery
pressure (mPAP) of>20mmHg,
with most ranging between 20
and 35 mm Hg andw3% to 5%
patients with mPAP >35 to 40
mm Hg (1,2). The morphological
appearance of vascular lesions in
COPD patients correlates with
the severity of PH, which is
similar to idiopathic pulmonary
arterial hypertension (IPAH) in
severe cases (3). Even under mod-
erate exercise conditions, COPD
patients typically show a rapid
further rise in mPAP values, indi-
cating loss of lung vascular disten-
sibility and/or vessel recruitment
capability (4). The rate of PH
progression in COPD is nor-
mally slow (an increase of <1
mm Hg per year [5]). Never-
theless, the presence of (even
moderate) PH is a strongVertex; has participated on steering committees
of Centocor, Forest, Gilead, GlaxoSmithKline,
medix; has participated in advisory teleconfer-
earch, Axon, Grey Healthcare, and Sudler and
Bayer, Forest, GlaxoSmithKline, Nycomed and
medical education programs for Incite, Foun-
Inova Health System, MedScape/WebMD,
s in Knowledge, St. John’s Hospital, St. Mary’s
go, University of Texas Southwestern, UpTo-
and has received royalties from Informa. Dr.
with Actelion, Bayer, Eli Lilly, Novartis, Pﬁzer,
ed consultancy and lecture fees from Actelion.
om and served as an advisory board member for
ring Eli Lilly, GlaxoSmithKline, and Pﬁzer; and
telion Pharmaceuticals, Merck, Bayer Schering,
ther authors have reported that they have no
of this paper to disclose.
013; accepted October 22, 2013.predictor of mortality in COPD, with an inverse correla-
tion between mPAP and/or pulmonary vascular resistance
(PVR) values and survival (2,6,7). A 5-year survival rate of
only 36% was reported for COPD patients with mPAP
values >25 mm Hg, with pulmonary hemodynamics being
a far stronger predictor of survival than the forced expira-
tory volume in 1 s (FEV1) or gas exchange variables (7). In
addition, enlarged pulmonary artery diameter, as detected
by computed tomography (CT) scan, predicts hospitaliza-
tion caused by acute COPD exacerbation (8).
Idiopathic pulmonary ﬁbrosis and diffuse parenchymal
lung disease. In idiopathic pulmonary ﬁbrosis (IPF), which
has a survival range of only 2.5 to 3.5 years, mPAP values of
>25 mm Hg were reported in 8.1% and 14.9% of patients,
respectively, upon initial workup (9,10). Higher percentages
are found in advanced (30% to 50%) and end-stage (>60%)
IPF cases (11–13). Among these, a small percentage may
present with mPAP values >40 mm Hg (w9% [14]). There
is only a poor or even no correlation between PH severity and
lung function impairment (14) or high-resolution CT
ﬁbrosis score (15). Increased dyspnea, deterioration of gas
exchange at rest, low capacity of lung to diffuse carbon
monoxide (DLCO) values, rapid desaturation upon exercise,
high brain natriuretic peptide (BNP) levels, gross right heart
dilation on chest radiography, and limitation of exercise
capacity caused by circulatory impairment have been linked to
PH development in IPF (12,16,17). Doppler-deﬁned PH
(systolic PAP >50 mm Hg [16]) and even invasive mPAP
values of >17 mm Hg (9) were associated with impaired
survival in IPF, with mPAP and forced vital capacity (FVC)
being independent predictors of survival (10). Rapid
progression of PH was reported in late stage diffuse paren-
chymal lung disease (DPLD)/IPF patients (13). In some
studies, the prognosis of PH in lung ﬁbrosis is not linked to the
mPAP values but to PVR (18) or cardiac index (CI), with CI
values <2.4 l/min/m2 being correlated with survival of only
a few months (19).
Combined pulmonary ﬁbrosis and emphysema and other
lung diseases. Combined pulmonary ﬁbrosis and emphy-
sema (CPFE) patients are particularly prone to PH devel-
opment, with estimates approaching 30% to 50% (19,20).
Here, severe PH and markedly impaired DLCO may
contrast with normal or mildly subnormal lung volumes and
absence of airﬂow obstruction. PH apparently contributes to
the functional proﬁle of CPFE (severe dyspnea, severely
impairment of gas transfer, and hypoxemia upon exercise)
and is associated with poor survival (19–21). At right heart
catheterization (RHC), PH was hemodynamically severe in
approximately one-half of the patients (mPAP >35 mm Hg
in 68%, >40 mm Hg in 48%), and the CI was the most
accurate prognostic determinant (19).
Several case reports and published series suggest a role for
PH, for example, in advanced sarcoidosis (22,23), severe
kyphoscoliosis, obesity-hypoventilation syndrome (24),
Langerhans cell histiocytosis (25,26), and to a lesser extent,
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D111in advanced lymphangioleiomyomatosis (27). Moreover, the
incidence of adult bronchopulmonary dysplasia (28) and
cystic ﬁbrosis (29) patients with PH is apparently
increasing.
Assessment and deﬁnition of PH due to chronic lung
diseases (group 3). Echocardiography is the initial
modality for noninvasive diagnosis of PH in COPD and
DPLD. Comparing echo cardiographic data with RHC in
lung disease patients, positive predictive values of 32% and
68%, respectively, and negative predictive values of 93% and
67%, respectively, were reported (30,31). Plasma levels of
BNP or the N-terminal prohormone of BNP are elevated in
severe COPD- and DPLD-associated PH, but lack sensi-
tivity in moderate PH and may be confounded by left heart
abnormalities (32). Nevertheless, BNP levels they were
found to be strongly predictive of mortality in a mixed
DPLD population (33).
RHC, the gold standard for PH diagnosis, should be
performed in patients with chronic lung disease when
1) evaluation for lung transplantation is deemed necessary; 2)
clinical worsening and progressive exercise limitation is
disproportionate to ventilatory impairment; 3) progressive gas
exchange abnormalities are disproportionate to ventilatory
impairment; 4) an accurate prognostic assessment is deemed
to be critical; 5) severe PH is suspected by noninvasive
measures and further therapy or inclusion in clinical trials or
registries are being considered; and 6) there is suspicion of left
ventricular systolic/diastolic dysfunction and categorization of
the pulmonary artery occlusion pressure might alter
management (adapted from Nathan and Cottin [34]).
Inhalation of iloprost and NO have been shown to reduce
mPAP and PVR in PH-IPF (35–37) and PH-COPD (38),
but there are currently no valid data to support routine use of
acute vasodilator testing in lung disease patients with PH.
Combining RHC with exercise testing in IPF, systolic
PAP measured by echocardiography correlated with peak O2
uptake, anaerobic threshold, peak O2 pulse, and ventilatory
equivalent for CO2, suggesting that PH has a negative
impact on exercise capacity (17). In COPD, exercise testing
may discriminate between an exhausted breathing reserve
caused by airﬂow limitation and an exhausted circulatory
reserve caused by PH, as detailed in the following text (39).
Use of the term “in proportion” PH in lung disease is
based on the assumption that the underlying parenchymal
remodeling process with accompanying hypoxia causes some
“natural” loss of overall vascular cross-sectional area and thus
an increase in PVR. “Out of proportion” PH, in contrast,
signals that the severity of PH is high in relation to the
degree of lung parenchymal abnormalities. Such a constel-
lation may reﬂect the fact that: 1) the chronic parenchymal
disease is a trigger of a progressive vascular remodeling
process, developing independently of lung function impair-
ment; or 2) the PH appears “by chance” in a patient with
lung disease at some stage but independently of this
comorbidity background. However, given the fact that a loss
of only >80% of normal lung structure will provoke PH,virtually any PAP value of >25 mm Hg may be considered
out of proportion.
Recommendations
It is suggested that the term “out of proportion” be aban-
doned and that the following deﬁnitions for COPD, IPF,
and CPFE (measurements undertaken at rest with supple-
mental oxygen if needed) be used:
1. COPD/IPF/CPFEwithout PH (mPAP<25mmHg);
2. COPD/IPF/CPFE with PH (mPAP 25 mm Hg;
PH-COPD, PH-IPF, and PH-CPFE); and
3. COPD/IPF/CPFE with severe PH (mPAP 35
mm Hg or mPAP 25 mm Hg with low CI (<2.0
l/min/m2); severe PH-COPD, severe PH-IPF, and
severe PH-CPFE).
The choice of mPAP 35 mm Hg as a cutoff for severe
PH is based on the following ﬁndings/assumptions, which
should be further addressed and putatively revised in future
studies:
1. The “severe PH group” includes only a minority of
chronic lung disease patients suspected of having signiﬁcant/
severe vascular abnormalities (remodeling) accompanying
the parenchymal disease (40). For COPD, this corresponds
to w1% of the entire population included in the NETT
(National Emphysema Treatment Trial) (41).
2. This degree of PH in COPD/IPF is assumed to
cause circulatory impairment that substantially worsens the
reduced exercise capacity caused by obstructive/restrictive
ventilatory impairment. A recent study documented the
fact that COPD patients with mPAP 40 mm Hg
deﬁnitely showed an exhausted circulatory reserve at the
end of exercise (documented by low mixed venous oxygen
saturation and reduced slope of the cardiac output/oxygen
consumption ratio), with breathing reserve maintained
(documented by low arterial PaCO2) (39). In contrast,
COPD patients without PH and those with moderate PH
(mPAP 31 mm Hg) are limited by ventilatory impairment
(exhaustion of breathing reserve, arterial PaCO2 increase at
the end of exercise), with circulatory reserve maintained
(39). Notably, although the FEV1 values were even higher
in the COPD/mPAP 40 mm Hg group than in the
COPD group without PH, the 6-min walk distance
(6MWD) values were drastically lower in COPD with
mPAP 40 mm Hg. In line with previous studies (1),
these ﬁndings strongly support the view that circulatory
impairment in COPD patients with severe PH markedly
adds to the limitation in exercise capacity. Similarly,
studies in IPF patients documented the fact that the
development of PH, in particular with mPAP values 35
mm Hg, resulted in signiﬁcantly lower values for capacity
of lung to diffuse carbon monoxide and arterial oxygena-
tion at rest, lower exercise capacity, and decline of arterial
oxygenation upon exercise, independent of lung function
tests (2,12,17).
Seeger et al. JACC Vol. 62, No. 25, Suppl D, 2013
Pulmonary Hypertension in Chronic Lung Diseases December 24, 2013:D109–16
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ventilatory impairment in the absence of any evidence of
lung airway or parenchymal disease, mainly in the form of
airway obstruction (42–45). In the largest of these studies
(171 IPAH patients; mean age 45 years; mean PVR 1,371
dynes  s  cm5), the mean FEV1 was 83% of predicted
value, and the FEV1/VC (Forced Expiratory Volume in 1 s/
Vital Capacity) ratio was 76%; in 22% of the total IPAH
patients, the FEV1/VC ratio was below 70% (45). Against
this background, randomized controlled trials in the ﬁeld of
PAH set exclusion criteria using pulmonary function testing
in the following ranges: total lung capacity <60% to 70% of
predicted values; FEV1 values <55% to 80% of predicted
values; or FEV1/FVC ratio <50% to 70%.
Moreover, lung diseases (in particular COPD) are
common conditions, and development of PAH in such
patients may not necessarily be the result of these diseases
(deﬁnition group 3 PH patients) but may be coincidental.
When there is uncertainty in the classiﬁcation of a patient
with lung disease and PH to group 1 (PAH) or group 3 (PH
caused by lung disease), the patient should be referred to
centers with expertise. Some suggested criteria for discrim-
ination between group 1 and group 3 are summarized
in Table 1.
Treatment of PH Caused by Chronic Lung Disease
(Group 3): Evidence for Appropriate
Beneﬁt/Risk Ratio of PAH-Focused Drugs?
The underlying lung disease should be treated according to
current guidelines. Within these guidelines, none of the
therapeutic measures focuses on the vascular component of
the disease, with the exception of long-term oxygen treat-
ment. In COPD patients with partial pressure of oxygen in
arterial blood (PaO2) values <60 mm Hg, long-term
oxygen treatment improved life expectancy, which might
be related to its retardation of PH development (46).Table 1 Differential Diagnosis Between Group 1 (PAH) and Group 3
Criteria Favoring Group 1 (PAH) Parameter
Normal or mildly impaired Ventilatory functio
FEV1 >60% predicted (COPD)
FVC >70% predicted (IPF)
Absence of or only modest airway or parenchymal
abnormalities
High-resolution CT
Features of exhausted circulatory reserve
Preserved breathing reserve
Reduced oxygen pulse
Low CO/VO2 slope
Mixed venous oxygen saturation at lower limit
No change or decrease in PaCO2 during exercise
*As to CT diagnosis, parenchymal changes linked to PVOD are to be discriminated from those associated
PH-IPF, but are then accompanied by major lung function and CT abnormalities.
CO/VO2 ¼ cardiac output/oxygen consumption ratio; COPD ¼ chronic obstructive pulmonary disease;
volume in 1 s; FVC ¼ forced vital capacity; IPF ¼ idiopathic pulmonary ﬁbrosis; PaCO2 ¼ partial press
hypertension; PVOD ¼ pulmonary veno-occlusive disease.In DPLD, long-term oxygen treatment is usually recom-
mended to maintain arterial oxygen saturation >90%;
however, this recommendation is not supported by a con-
trolled trial. As for PAH-focused drugs, the current state
may be summarized in the following text.
Vasoactive therapy in lung ﬁbrosis. Any vasodilator may
worsen gas exchange in lung-diseased patients because of
interference with hypoxic vasoconstriction, which diverts
pulmonary blood ﬂow from more seriously to less seriously
affected lung segments. However, vasodilators may prefer-
entially access the better ventilated and oxygenated areas of
the ﬁbrotic lung because of their mode of distribution
(inhaled iloprost, treprostinil, or nitric oxide [35,37,47]) or
may enhance normoxic vasodilation (the phosphodiesterase
5 inhibitor sildenaﬁl [36,48]), which may be advantageous in
this respect. Long-term studies using prostanoids in lung
ﬁbrosis-associated PH are missing, however. In IPF, the
nonselective endothelin receptor antagonist (ERA) bosentan
was well tolerated (49–51), but failed to improve the pre-
deﬁned endpoint “time to occurrence of lung ﬁbrosis
worsening” in a phase III trial (51). Negative trial results
were also reported for the selective ERA ambrisentan
(ARTEMIS-IPF [Placebo-Controlled Study to Evaluate
Safety and Effectiveness of Ambrisentan in Idiopathic
Pulmonary Fibrosis]) and macitentan (MUSIC [Macitentan
Use in an Idiopathic Pulmonary Fibrosis Clinical study]) in
IPF. The ARTEMIS-IPF study was terminated because of
an increased rate of disease progression and respiratory
hospitalization (52). Within this entire IPF group, 11% of
patients presented with PH (mPAP 25 mm Hg), which
did not affect the endpoint estimates. Based on these results,
the European Medicines Evaluation Agency recently con-
traindicated the use of ambrisentan in IPF patients,
regardless of the presence of PH. No results are currently
available from a bosentan trial particularly focusing on IPF-
associated PH (B-PHIT [Bosentan in PH in Interstitial
Lung Disease]; NCT00637065).(PH Due to Lung Disease) PH
Criteria Favoring Group 3 (PH Due to Lung Disease)
n Moderate to very severe impairment
FEV1 <60% predicted (COPD)
FVC <70% predicted (IPF)
scan* Characteristic airway and/or parenchymal abnormalities
Features of exhausted ventilator reserve
Reduced breathing reserve
Normal oxygen pulse
Normal CO/VO2 slope
Mixed venous oxygen saturation above lower limit
Increase in PaCO2 during exercise
with DPLD.y Features of exhausted circulatory reserve are also noted in severe PH-COPD and severe
CT ¼ computed tomography; DPLD ¼ diffuse parenchymal lung disease; FEV1 ¼ forced expiratory
ure of carbon dioxide in arterial blood; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary
Table 2 Management of PH in the Setting of Chronic Lung Disease
Underlying Lung Disease mPAP <25 mm Hg at Rest mPAP 25 and <35 mm Hg at Rest mPAP 35 mm Hg at Rest*
COPD with FEV1 60% of predicted
IPF with FVC 70% of predicted
CT: absence of or only very modest airway
or parenchymal abnormalities
No PH
No PAH treatment
recommended
PH classiﬁcation uncertain
No data currently support treatment
with PAH-approved drugs
PH classiﬁcation uncertain: discrimination
between PAH (group 1) with concomitant
lung disease or PH caused by lung
disease (group 3)
Refer to a center with expertise in both PH
and chronic lung disease
COPD with FEV1 <60% of predicted
IPF with FVC <70% of predicted
Combined pulmonary ﬁbrosis and
emphysema on CT
No PH
No PAH treatment
recommended
PH-COPD, PH-IPF, PH-CPFE
No data currently support treatment
with PAH-approved drugs
Severe PH-COPD, severe PH-IPF, severe
PH-CPFE
Refer to a center with expertise in both PH
and chronic lung disease for individualized
patient care because of poor prognosis;
randomized controlled trials required
*Lower PA pressures may be clinically signiﬁcant in COPD/DPLD patients with depressed cardiac index or right ventricular dysfunction.
CPFE ¼ combined pulmonary ﬁbrosis and emphysema; mPAP ¼ mean pulmonary artery pressure; other abbreviations as in Table 1.
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D113In a small open-label study in IPF patients with PH,
sildenaﬁl was noted to improve 6MWD (53). In a controlled
trial of sildenaﬁl in advanced IPF, the primary outcome
variable (proportion of patients with 6MWD increase
>20%) was not met, but arterial oxygenation, DLCO,
dyspnea, and quality of life improved (STEP-IPF [Sildenaﬁl
Trial Of Exercise Performance In Idiopathic Pulmonary
Fibrosis]) (48). A pre-speciﬁed analysis of the available echo
cardiographic data from this trial (119 of 180 patients)
showed that sildenaﬁl preserved the 6MWD and improved
the St. George’s Questionnaire score compared with placebo
in the subgroup of 22 patients with right ventricular systolic
dysfunction (54). Additional evidence is expected from trials
focusing on the use of sildenaﬁl in IPF patients with asso-
ciated PH (NCT00625079; recruitment status currently
unknown).
Pre-clinical and clinical ﬁndings support the view that
both endothelin receptor antagonists and phosphodiesterase 5
inhibitors possess marked antiproliferative capacity in the
pulmonary vasculature in addition to their vasodilatory effects
(55). This ﬁeld is currently extended by the use of direct
stimulators and activators of the soluble guanylate cyclase,
working even at sites with inactivated NO axis and exerting
strong pulmonary vasodilatory and antiproliferative potency
in experimental models of PH (56). Phase II and III trials in
both PAH and chronic thromboembolic pulmonary hyper-
tension (CTEPH) patients demonstrated the efﬁcacy of the
soluble guanylate cyclase stimulator riociguat in improved
exercise capacity (primary outcome variable) and several
secondary endpoints (57–60). A recent phase II trial missed
the primary endpoint (reduction in PAP) but demonstrated
the efﬁcacy of riociguat in decreasing PVR but also systemic
vascular resistance and in increasing cardiac output and
6MWD in PH-DPLD (61); a randomized controlled trial
focusing on PH-DPLD is in preparation.
Occasional cases of improved hemodynamic data and,
more rarely, clinical improvement with PH-speciﬁc therapy
in CPFE patients have been reported (19,62). Randomized
controlled trials are currently missing.
Vasoactive therapy in COPD. In COPD, pulmonary
vasodilation without deterioration of gas exchange is morechallenging than in lung ﬁbrosis caused by the presence of
low ventilation/perfusion ratio areas (63). Inhaled prosta-
noids may acutely reduce mPAP and PVR while largely
maintaining gas exchange in PH-COPD (64); however,
long-term clinical trials have not been reported. In COPD
patients with mild PH, bosentan caused deterioration of gas
exchange with lack of improvement in peak oxygen uptake,
exercise capacity, and quality of life in a small randomized
controlled trial (65). In 1 small trial, improved exercise
capacity upon treatment of PH-COPD patients with
bosentan was reported (66). Robust data for the effect of
ERAs on pulmonary hemodynamics and exercise tolerance
in PH-COPD are thus lacking.
Short-term administration of sildenaﬁl in PH-COPD
improved hemodynamics but deteriorated gas exchange
(67). One month of sildenaﬁl treatment in COPD patients
without PH did not affect 6MWD and VO2 peak but wors-
ened arterial oxygenation and quality of life (68,69). A recent
randomized controlled trial of sildenaﬁl added to pulmonary
rehabilitation also failed to show improvement in exercise
tolerance in COPD patients without severe PH (70). In
contrast, 1 small randomized controlled trial reported
a decrease in PAP, accompanied by an increase in 6MWD,
upon long-term use of sildenaﬁl in patients with severe PH-
COPD (71). Thus, there is deﬁnitely a lack of evidence of
a long-term beneﬁcial effect of sildenaﬁl in COPDpatients in
the absence of severe PH, whereas the impact of this agent on
severe PH-COPD is still not settled.
When assessing the acute effects of riociguat in PH-
COPD, improvement of pulmonary hemodynamics with-
out major deterioration of gas exchange (multiple inert gas
elimination technique technology) was noted (H.A. Gho-
frani et al., nonpublished results, October 2013), thus war-
ranting future studies in this indication.
Recommendations for COPD and Lung Fibrosis
Long-term randomized controlled trials focusing on patients
with severe PH and chronic obstructive or restrictive lung
diseases are needed. Only such an approach will provide
reliable data for the use of PAH-approved drugs in these
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D114patients. In such studies, obstructive and restrictive lung
diseases should be investigated separately because of the
major differences in underlying pathophysiology. Based on
lung function testing, cardiopulmonary exercise testing, and
clinical and CT evidence for lung airway or parenchymal
disease and severity of PH, the following groups of PH
patients are to be distinguished with respect to classiﬁcation
and therapy recommendations (Table 2):
1. Patients with milder forms of obstructive or restrictive
lung disease and minor impairment of lung function testing,
in whom CT analysis shows no gross parenchymal or airway
abnormalities and who present with clinically relevant
PH should be speciﬁed. Whether such patients have PAH
(group 1) with concomitant lung disease or PH caused by
lung disease (group 3) is a diagnostic dilemma (see the
previously mentioned conditions). Therefore, these patients
should be referred to an expert unit, where a comprehensive
diagnostic workup should be made, including high-
resolution CT, hemodynamics, complete lung function
testing, and detailed cardiopulmonary exercise testing.
Chance association of PH is much less likely in IPF than in
COPD.
2. Patients with more severe obstructive or restrictive
lung disease (IPF with FVC <70% predicted; COPD with
FEV1 <60% predicted) and accompanying less severe PH
(mPAP 25 mm Hg and <35 mm Hg; PH-COPD, PH-
IPF) and patients with combined pulmonary ﬁbrosis and
emphysema and accompanying PH (mPAP 25 mm Hg
and <35 mm Hg; PH-CPFE; lung volumes may be
preserved in these patients) should be classiﬁed. This group
represents the majority of patients presenting with chronic
lung disease and PH. Here, no data currently support
therapy with PAH-approved drugs. Moreover, as the limi-
tation in exercise capacity in these patients is largely based
on ventilatory and not circulatory impairment, any beneﬁt
from PAH treatment is questionable. In addition, vasodi-
lators may impair gas exchange, particularly in COPD.
This does not exclude the fact that vascular changes may
contribute to disease progression and may become a future
therapeutic target from this angle, but controlled clinical
trials addressing this topic are currently missing.
3. Patients with more severe obstructive or restrictive lung
disease or a combination thereof and severe PH as deﬁned in
the previous text (mPAP 35 mm Hg; severe PH-COPD;
severe PH-IPF; severe PH-CPFE) must be distinguished.
These patients have a poor prognosis and should be referred
to a center with expertise in both PH and chronic lung
disease for individualized patient care. In some of these
patients, a detailed analysis of hemodynamics may suggest
that a low or low normal cardiac output (baseline conditions)
and/or an inadequately increasing cardiac output upon
exercise testing may substantially contribute to the limitation
of peak oxygen uptake and, thus, physical activity and that
the augmented right heart afterload is the main cause for the
hemodynamic compromise. These patients should preferably
be included in randomized controlled trials if available. Inaddition, for the time being, use of a PAH-approved drug on
a compassionate treatment basis may be considered for this
subpopulation, with thorough monitoring of gas exchange
(PaO2, PaCO2) and inclusion in prospective registries. Gas
exchange may be found to be deteriorated (caused by inter-
ference with the hypoxic vasoconstriction) or improved
(caused by normoxic vasodilatation and higher central venous
oxygen saturation upon drug-induced CI increase).
4. Patients with end-stage obstructive or restrictive lung
diseases or a combination thereof should be included. In these
patients, any use of PAH-approved drugs was hitherto largely
discouraged because of limited life expectancy. However, the
recent ﬁnding that bridging to transplantation may include
the use of “awake extracorporeal membrane oxygenation”
(extracorporeal membrane oxygenation) (72) and that long-
term noninvasive (nocturnal) home mechanical ventilation
may substantially prolong the life expectancy of these patients
challenges this view. Controlled trials should address the
question whether PAH-approved drugs may improve exer-
cise capacity and quality of life, prolong time to clinical
worsening, and improve survival or bridging to trans-
plantation in patients with end-stage obstructive or restrictive
lung diseases and accompanying PH receiving mechanical
ventilatory or extracorporeal membrane oxygenation support.
Speciﬁc Aspects of Sarcoidosis,
Systemic Sclerosis, and Rare Lung Diseases
The prevalence of pulmonary hypertension in sarcoidosis
(PH-SA) was approximately 5% in the only series of unse-
lected patients (73). However, PH was reported in 47% of
sarcoidosis patients with exertional dyspnea disproportionate
to pulmonary function test results, with low PaO2 and low
DLCO levels, indicating the presence of PH (74) and, in up
to 74% of sarcoidosis patients, listed lung transplantation
(75). PH-SA has a 5-year survival of w60% (76), with
PH being an independent, poor prognostic determinant.
PH may occur with little or no evidence of interstitial
lung disease (75), reﬂecting considerable pathophysiologic
heterogeneity. Mechanisms contributing to the pathogenesis
of PH-SA include ﬁbrotic ablation of the pulmonary
vasculature, extrinsic compression of the central pulmonary
vessels by lymphadenopathy or mediastinal ﬁbrosis, pul-
monary veno-occlusive disease, left ventricular dysfunction,
portopulmonary hypertension, and an intrinsic sarcoid vas-
culopathy caused by granulomatous invasion of pulmonary
vessels (76). The management of PH-SA includes treatment
of the underlying sarcoidosis, reversal of resting hypoxemia,
and referral for lung transplantation in selected patients.
As to vasoactive therapy, acute and chronic improvements in
pulmonary hemodynamics and exercise capacity have been
reported for inhaled NO, intravenous epoprostenol, bosen-
tan, sildenaﬁl, and inhaled iloprost (77–79); however, larger
controlled trials are missing. Referral of patients with
PH-SA to expert centers is strongly recommended, with
treatment decisions made on a case by case basis.
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D115Patients with systemic sclerosis occasionally develop both
pulmonary ﬁbrosis and PH, with hemodynamic character-
istics generally comparable to that of IPAH (80). Whether
PH should be classiﬁed as group 1 or 3 in this setting is
often unclear and should be judged in expert centers. Only
retrospective studies regarding PAH therapy are available in
patients with systemic sclerosis, PH, and interstitial lung
disease, with unclear beneﬁt (81).
For patients with rare lung diseases, in whom any random-
ized controlled trial is very unlikely to be undertaken in the near
future, registries are strongly encouraged to provide reliable
data about the prevalence of PH in these populations and to
provide a hypothesis as to whether PAH-focused therapy
might be of any clinical beneﬁt. Individual responses to treat-
ment with PAH-approved drugs were reported for patients
with severe kyphoscoliosis (82), obesity-hypoventilation
syndrome (24), Langerhans cell granulomatosis (25,26), and
advanced lymphangioleiomyomatosis (27).
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